Meeting
2020 Gastrointestinal Cancers Symposium
Postoperative adjuvant chemotherapy with S‑1 versus SOX/XELOX regimens for pStage III gastric cancer: A cohort study.
Authors
Nobuhiro Tsuchiya
Department of Surgery, Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan
Nobuhiro Tsuchiya , Chikara Kunisaki
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Esophageal and Gastric Cancer and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 358)
Abstract #
358
Poster Bd #
D13
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Phase III trial comparing XELOX regimen (oxaliplatin plus capecitabine) versus EOX regimen (epirubicin, oxaliplatin and capecitabine) as first-line treatment for advanced gastric cancer: EXELOX trial.
First Author: Weijian Guo
Poster
2018 ASCO Annual Meeting
Capecitabine plus oxaliplatin versus capecitabine plus oxaliplatin with concurrent radiotherapy in the treatment of gastric cancer after D2 gastrectomy.
First Author: Congying Xie
Poster
2018 Gastrointestinal Cancers Symposium
Extended outcomes of intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastases.
First Author: Dexter Yak Seng Chan
Poster
2017 ASCO Annual Meeting
Phase III trial to evaluate the efficacy of neoadjuvant chemotherapy with S-1 plus oxaliplatin followed by D2 gastrectomy with adjuvant S-1 in locally advanced gastric cancer: Japan Clinical Oncology Group study JCOG1509 (NAGISA trial).
First Author: Masanori Tokunaga